S-nitroso-N-acetyl-penicillamine | 273921-90-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: S-nitroso-N-acetyl-penicillamine
• 英文别名: SNAP；S-nitroso-N-acetyl-L-penicillamine；S-Nitroso-N-acetylpenicillamine；(2R)-2-acetamido-3-methyl-3-nitrososulfanylbutanoic acid
• CAS: 273921-90-7
• 化学式: C₇H₁₂N₂O₄S
• 分子量: 220.249
• InChiKey: ZIIQCSMRQKCOCT-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  S-nitroso-N-acetyl-penicillamine 生成 N-乙酰基-3-(亚硝基硫代)-D-缬氨酸
  参考文献：
  名称：

  Nitric oxide-releasing packaging membranes

  摘要：

  开发并测试了具有抗菌性能的可生物降解复合膜，由纳米纤维素纤维、壳聚糖和硝基乙酰青霉胺（SNAP）组成，用于食品包装应用。硝基氧化物供体SNAP被封装到完全分散的壳聚糖中，与纳米纤维素纤维（CNF）充分混合，制备成复合膜。制备的膜中壳聚糖和SNAP均匀分散在纳米纤维素纤维中，通过扫描电子显微镜（SEM）和化学发光氧化物分析仪确认。没有SNAP的膜的水蒸气透过率低于带有SNAP的膜。添加SNAP导致2层和3层膜结构的杨氏模量降低。SNAP包含的膜的抗菌性能评估显示对肠球菌、金黄色葡萄球菌和李斯特菌的细菌菌株有有效的抑制区，并展示了其在食品包装中的潜在应用。

  公开号：

  US10494493B1
• 作为产物：
  描述：

  N-acetyl-D-penicillamine 在 氧气 、 氧化亚氮 作用下， 以 水 为溶剂， 生成 S-nitroso-N-acetyl-penicillamine
  参考文献：
  名称：

  含氧•NO 溶液对硫醇和胺的亚硝化机理：亚硝化中间体的性质

  摘要：

  研究了生理 pH 值下含氧•NO 溶液对各种硫醇和吗啉的亚硝化作用。使用停流技术测定亚硝基化合物的形成速率和产率。该过程的化学计量已确定，由 4•NO + O2 + 2RSH/2RR'NH → 2RSNO/2RR'NNO + 2NO2- + 2H+ 给出。动力学研究表明，速率定律是-d[O2]/dt = k1[•NO]2[O2]，其中k1 = (2.54 ± 0.26) × 106 M-2 s-1 和-d[•NO]/dt = 4k1[•NO]2[O2]，其中 4k1 = (1.17 ± 0.12) × 107 M-2 s-1，与存在的底物类型无关。动力学结果与•NO 的自氧化得到的结果相同，表明•NO 的自氧化速率不受硫醇和胺的存在的影响。•NO 的亚硝化作用仅在氧气存在下发生，因此，在生物系统中，硫醇和氧化•NO 溶液形成S-亚硝基硫醇的速率相对较慢。在生理条件下 [•NO] < 1 μM

  DOI：

  10.1021/ja9536680

文献信息

• [EN] S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES<br/>[FR] COMPOSÉS DE S-NITROSOMERCAPTO ET DÉRIVÉS APPARENTÉS
  申请人：GALLEON PHARMACEUTICALS INC

  公开号：WO2009151744A1

  公开（公告）日：2009-12-17

  The present invention is directed to mercapto-based and S- nitrosomercapto-based SNO compounds and their derivatives, and their use in treating a lack of normal breathing control, including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions.

  本发明涉及基于巯基和S-亚硝基巯基的SNO化合物及其衍生物，以及它们在治疗正常呼吸控制缺失方面的用途，包括治疗与睡眠、肥胖、某些药物和其他医疗状况相关的呼吸暂停和低通气。
• Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
  申请人：——

  公开号：US20010041726A1

  公开（公告）日：2001-11-15

  The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B 4 (LTB 4 ) receptor antagonists, leukotriene A 4 (LTA 4 ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

  本发明描述了新颖的硝化和/或亚硝化环氧合酶2（COX-2）抑制剂以及包含至少一种硝化和/或亚硝化环氧合酶2（COX-2）抑制剂的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或可选地，至少一种治疗剂，如类固醇、非甾体抗炎化合物（NSAID）、5-脂氧合酶（5-LO）抑制剂、白三烯B4（LTB4）受体拮抗剂、白三烯A4（LTA4）水解酶抑制剂、5-HT激动剂、3-羟基-3-甲基戊二酰辅酶A（HMGCoA）抑制剂、H受体拮抗剂、抗肿瘤药物、抗血小板药物、解充血剂、利尿剂、镇静或非镇静抗组胺药、诱导型一氧化氮合酶抑制剂、阿片类药物、镇痛剂、幽门螺杆菌抑制剂、质子泵抑制剂、异前列腺素抑制剂以及其混合物。本发明还提供了包含至少一种母体COX-2抑制剂和至少一种一氧化氮供体的新型组合物，以及可选地，至少一种治疗剂。本发明还提供了用于治疗炎症、疼痛和发热的工具和方法；用于治疗和/或改善COX-2抑制剂的胃肠道特性；用于促进伤口愈合；用于治疗和/或预防肾毒性；以及用于治疗和/或预防由于环氧合酶-2水平升高而导致的其他疾病的工具和方法。
• DIURETICS
  申请人：ALI Amjad

  公开号：US20100029678A1

  公开（公告）日：2010-02-04

  A compound having the structure wherein X is selected from the group consisting of: a bond, —NHCH 2 (CH 2 ) n CH 2 OC(O)—, —CH 2 NHC(O)CH 2 NHC(O)—, —CH 2 OC(O)—, —OCH(CH 3 )OC(O)—, —OCH 2 OC(O)—, —O—, —NR 1 —, —CR 1 R 3 —, —(CH 2 ) p —, —(CH 2 ) q NR 1 C(O)—, —CHR 5 NR 2 C(O)—, —(CH 2 ) q C(O)—, —(CH 2 ) q C(O)—, —(CH 2 ) q C(O)NR 1 —, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating, hypertension.

  具有以下结构的化合物： 其中 X 是从以下组中选择： 一个键，—NHCH 2 (CH 2 ) n CH 2 OC(O)—, —CH 2 NHC(O)CH 2 NHC(O)—, —CH 2 OC(O)—, —OCH(CH 3 )OC(O)—, —OCH 2 OC(O)—, —O—, —NR 1 —, —CR 1 R 3 —, —(CH 2 ) p —, —(CH 2 ) q NR 1 C(O)—, —CHR 5 NR 2 C(O)—, —(CH 2 ) q C(O)—, —(CH 2 ) q C(O)—, —(CH 2 ) q C(O)NR 1 —， 或其药物可接受的盐，以及使用这些化合物治疗高血压的方法。
• Nitrosated proton pump inhibitors, compositions and methods of use
  申请人：NitroMed, Inc.

  公开号：US20040024014A1

  公开（公告）日：2004-02-05

  The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti- Helicobacter pylori properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating bacterial infections and/or viral infections.

  该发明描述了新颖的亚硝化质子泵抑制剂化合物及其药用盐，以及包含至少一种亚硝化质子泵抑制剂化合物的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种亚硝化质子泵抑制剂化合物和至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种亚硝化质子泵抑制剂化合物，可选地至少一种一氧化氮供体和/或至少一种治疗剂的新型套装。该发明还提供了治疗胃肠道疾病的方法；促进溃疡愈合；减少溃疡复发；改善质子泵抑制剂的胃保护性能、抗幽门螺杆菌性能或抗酸性能；减少或减轻与非甾体类抗炎化合物使用相关的胃肠毒性；治疗细菌感染和/或病毒感染。
• Compositions and methods of using them
  申请人：——

  公开号：US20030219494A1

  公开（公告）日：2003-11-27

  The present invention is directed to compositions and methods for inducing, promoting or otherwise facilitating pain relief. More particularly, the present invention relates to the use of a compound which either directly or indirectly prevents, attenuates or reverses the development of reduced opioid sensitivity, together with a compound which activates the opioid receptor that is the subject of the reduced opioid sensitivity, in methods and compositions for the prevention or alleviation of pain, especially in neuropathic conditions and even more especially in peripheral neuropathic conditions such as painful diabetic neuropathy (PDN).

  本发明涉及诱导、促进或以其他方式促进缓解疼痛的组合物和方法。更具体地，本发明涉及使用一种化合物，该化合物直接或间接地防止、减轻或逆转降低阿片受体敏感性的发展，以及一种激活受降低阿片受体敏感性影响的阿片受体的化合物，用于预防或缓解疼痛的方法和组合物，特别是在神经病理性疼痛条件下，尤其是在外周神经病理性疼痛条件下，如疼痛性糖尿病性神经病变（PDN）中。